What the business is, and whether it's a good one at a fair price.
Sells over-the-counter consumer healthcare products in India, with four reporting segments. OTC Products is the core franchise, contributing 65.3% of FY26 segment revenue at Rs 328.32 crore, built around pain-relief brands including Back Pain Roll On and Head Roll On, which grew 12% and 21% respectively. Women's Hygiene & Personal Care accounts for 27.8% (Rs 139.91 crore), led by the Comfy XL variant which grew 44%. Beverages make up 6.3% (Rs 31.56 crore) and Others 0.6%. Only OTC Products is profitable at the segment level (EBIT Rs 83.44 crore), while Women's Hygiene, Beverages and Others each reported negative EBIT in FY26. Distribution was expanded during the year — stockist network up 9%, outlet coverage up 12%, and 44,000 new chemist outlets added, with a stated target of 100,000 chemist outlets by September 2027. New product launches included razors, antiseptic plaster, ortho pain oil and a nasal spray. The cost base is dominated by other operating expenses at 23.6% of revenue and materials at 21.2%, with employees at 12.7% and depreciation at 1.3%; capex was 10.9% of revenue.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from AMRUTAJAN HEALTH LTD's filed financials and exchange disclosures
AMRUTAJAN HEALTH LTD is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol AMRUTANJAN.
Yes. Over the trailing twelve months AMRUTAJAN HEALTH LTD reported a net profit of ₹54 Cr on revenue of ₹511 Cr.
Yes. The dividend yield is 0.93% at the current price. It paid out 23% of its profit as dividend in FY26.
Effectively yes. It holds ₹11 Cr more cash than debt. Debt stands at 0.00× equity.
On trailing P/E, AMRUTAJAN HEALTH LTD ranks 76 of 169 in Pharmaceuticals — cheaper than 55% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session AMRUTAJAN HEALTH LTD moves 0.90% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by AMRUTAJAN HEALTH LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
